China's latest boom is sounding alarm bells in America
It marked a watershed moment for the pharmaceutical sector, which had long written off China as a nation that excelled in drug manufacturing and 'copycat' treatments but not medicine discovery.
Akeso's debut on the world stage has been described as a 'DeepSeek' moment for the industry – a reference to the sudden emergence of a highly advanced AI chatbot out of China earlier this year, which took US tech giants by surprise and wiped close to $US1 trillion ($1.5 trillion) off global stock markets.
Summit's shares are up more than 600 per cent since first announcing the lung cancer trial results.
'The two large innovators in our industry today are the US and China,' Sir Pascal Soriot, the boss of AstraZeneca, said in March. 'China is, I think over the next five to 10 years, going to emerge as really a driving force for innovation in our sector.'
It sets the stage for a growing tussle between the US and China over the future of drug development. Donald Trump has been clear that he wants pharmaceutical giants to be investing more in America. Biopharmaceutical companies and their suppliers account for 4.9 million jobs and are worth around $US1.65 trillion ($2.6 trillion) to the US.
However, drug companies are increasingly turning east when it comes to investing in new drugs and clinical trials. Not only is China becoming an easier place to research and create new drugs, but the Trump administration is also shaking faith in the US.
Vaccine sceptic health secretary Robert F Kennedy Jr has prompted much anxiety in the industry. By contrast, China is 'very business friendly and stable' Novartis boss Vas Narasimhan said in May.
Drugs boom
Beijing has been attempting to win more pharma investment for years – and specifically attempting to boost funding for drug innovation. Drug discovery was a key pillar of the 'Healthy China 2030″ strategy unveiled in 2016, aimed at helping the country cope with its ageing population.
Loading
The focus has already paid dividends. Over the past three years alone, the number of Chinese drugs in development has doubled to 4,391. Almost half are either novel drugs or something known as a 'fast-follower', where treatments are quickly developed on the back of breakthroughs by rivals.
According to Barclays, the number of so-called 'first-in-class' drugs under development in China rose to around 120 last year, having been in the single digits in 2015. First-in-class essentially measures the level of innovation by looking at the highest development stage a drug has reached and the earliest time it reached that stage.
The growth in China is unmatched. While the US, which has long been regarded as the world leader in drug discovery, has more first-in-class drugs in development, at 151, the growth rate has been much slower.
'The shift isn't incremental, it's tectonic,' says Abhishek Jha, the founder of life sciences data company Elucidata.
One crucial part of Beijing's push to drive more drug discovery has been speeding up clinical trials. In China, regulators allow businesses to get studies up and running quicker, and then update them as they progress.
This can provide early data on new drugs, which is a major draw for multinational companies looking for novel treatments that show signs of working well.
It has sparked a boom in studies taking place in China. According to figures from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), China accounted for around 18 per cent of clinical trials sponsored by companies in 2023 compared to just 5 per cent in 2013. Meanwhile, the US proportion has dipped from 28 per cent to 23 per cent.
Clinical trial enrolment in China is surging, with around 40 per cent now having more than 100 participants.
Bitter pill
Fewer regulatory barriers are just one of a number of reasons pharma companies are turning to China. Workers, too, are less averse to working unsociable hours than they would be in Western nations.
Shirley Chen, a Barclays analyst, says: 'Chinese scientists may be happier to accept very long work hours and people like hospital personnel [where trials take place] are actually okay to do night shifts.'
Major drug giants are now scouring China for potential deals. The likes of GSK, AstraZeneca and Merck have all struck deals worth more than $US1 billion to get the rights to develop and sell Chinese drugs outside the country.
The rise of China's pharmaceutical industry has started to raise alarm bells in the US. Trump may be focused on returning manufacturing jobs to the US, yet some say he should be concerned that more high-quality jobs and research posts are starting to drift to China.
'Five years ago, US pharmaceutical companies didn't license any new drugs from China,' Scott Gottlied, the former Food and Drug Administration commissioner, wrote earlier this month. 'By 2024, one third of their new compounds were coming from Chinese biotechnology firms.'
He warned that the shift of clinical trials to Asia could undermine innovation in the US as companies choose to 'divert funds that might otherwise bolster innovation hubs such as Boston's Kendall Square or North Carolina's Research Triangle'.
Loading
'The US biotechnology industry was the world's envy, but if we're not careful, every drug could be made in China.'
While Trump exempted most countries' pharmaceutical industries from tariffs in his 'liberation day' blitz, China was not spared. That means physically manufacturing drugs for the US in China is out of the question, for now at least.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
2 hours ago
- Sydney Morning Herald
Radiation dangers of three nuclear sites struck by the US
The technology centre has three small Chinese-built research reactors, a lab which makes the uranium hexafluoride gas, a reactor fuel manufacturing plant and a nuclear waste storage facility. In 2021, the IAEA found a plant at Isfahan created uranium metal, which can be used to make the core of a nuclear weapon. 'Uranium metal is less chemically hazardous than uranium hexafluoride gas, but it poses a significant radiation risk,' Diaz-Maurin said. He warned the radiological consequences of a strike on research reactors could be significant. The IAEA said there was no off-site rise in radiation levels after earlier Israeli bombing of Isfahan. Natanz Risk of radioactive contamination from the bombing of Iran's main facility for uranium enrichment at Natanz is very low, according to Diaz-Maurin. Enrichment occurs is when uranium is centrifuged at high speeds to process it into weapons-grade material. About 15,000 underground enrichment centrifuges were already destroyed or badly damaged by Israeli bombing. The centrifuges contain tiny amounts of uranium hexafluoride, which is one of the most corrosive substances on Earth. The gas also creates toxic fluoride when it comes into contact with moisture. A hexafluoride gas storage facility was also already damaged, resulting in radiological and chemical contamination contained at the site. Loading 'The main risk inside the storage facility is the chemical toxicity of uranium hexafluoride gas and fluoride compounds generated in contact with water,' Diaz-Maurin wrote. 'The radiological risk from enriched uranium at Natanz is likely to be much smaller than the chemical toxicity from the fluorine.' He warned that although uranium hexafluoride was not directly fissile – or able to undergo nuclear fission – damage could cause a dangerous explosion. 'If moisture enters transport or storage cylinders, uranium, especially enriched uranium, becomes more reactive. 'This could potentially lead to a chemical explosion of the cylinders, resulting in a significant dispersion of uranium hexafluoride gas into the facility and possibly into the environment – a scenario possible even without an attack.' Experts told Reuters the slightly radioactive gas did not tend to travel far if released. Fordow B2 bombers struck the underground Fordow facility with at least six 30,000-pound bunker-buster bombs, The New York Times reported. Risk of off-site radiation contamination from the facility is also very low because it's an enrichment plant. Fordow is also built within a mountain 90 metres underground, further reducing the risk contamination would spread. 'Should a subterranean enrichment facility or reactor be hit by one or more bunker-busters, it is unlikely that there would be significant contamination beyond the confines of the site,' Dr Simon Bennett, director of the civil safety and security unit at the University of Leicester, said. Loading Experts are most concerned about the prospect of a strike on Bushehr nuclear power plant. A strike which pierced the plant's nuclear reactor or interrupt power supply could release radioactive material into the atmosphere, contaminate the waters of the Gulf and trigger evacuation of people hundreds of kilometres from the site, Grossi warned. He underlined the IAEA's belief that armed attacks on nuclear facilities should never take place.
The Advertiser
4 hours ago
- The Advertiser
Ford might develop future engines with outside firms, says executive
A senior Ford executive thinks customers no longer separate brands based on their petrol and diesel engines, and this might lead to the automaker developing new engines with suppliers or, maybe, rivals. According to Automotive News John Lawler, Ford's vice chair overseeing strategy, partnerships and alliances, told the Bernstein Strategic Decisions Conference, "I don't think that consumers really think about powertrains the way they did 30 years ago". He told the conference, "Where [internal combustion engines] defined what a vehicle was — the horsepower, the displacement, the torque and everything about the vehicle — I think a lot of that is gone". Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. Part of this, Mr Lawler believes, is down to electrification, which allows automakers to increase power and torque, while reducing CO2 emissions, with hybrid or plug-in hybrid drivetrains. Mr Lawler posits this might lead automakers, including Ford, to develop next-generation engines with other companies. Doing so would save money that could help them compete with Chinese automakers. According to the vice chair, Ford needs "to be competitive against them not only on speed of development, software capability, electrical architecture capability, but also overall electrification capability". In 2022 Renault merged its Horse drivetrain division with that of Geely's Aurobay in the hopes of attracting customers for its engines and transmissions outside of the two automakers' stable of brands, which include Dacia, Volvo, Zeekr, and Lotus. It should be noted engine and drivetrain sharing between rival automakers, while not the norm, isn't completely unheard of. In the early 2000s Ford developed a V6 turbo-diesel in conjunction with the PSA Group, which was used in a wide variety of vehicles, including Australian Ford Territory, as well as the Citroen C5, Peugeot 407 and 607, and a whole host of Jaguar and Land Rover models. Other times, manufacturers just sign a supply agreement to fill a hole in their drivetrain lineup, such as when Toyota Europe used BMW diesel engines in the 2010s for a number of models, including the RAV4. Small manufacturers often rely exclusively on engines from other car makers, with Lotus, for example, using mills from Rover, Toyota and Mercedes-Benz. Ford is no stranger to collaborating with other car makers in other areas too. It currently shares a number of platforms with the Volkswagen Group, with the Volkswagen Amarok based on the Ford Ranger, and Volkswagen Transporter based on the Ford Transit Custom. Going the other way, the Ford Transit Connect is based on the Volkswagen Caddy, and the European Ford Explorer and Capri EVs are based Volkswagen MEB architecture. Prior to all this, Ford jointly developed a 10-speed automatic transmission for use in full-size pickup trucks with cross-town rival GM. MORE: Everything Ford Content originally sourced from: A senior Ford executive thinks customers no longer separate brands based on their petrol and diesel engines, and this might lead to the automaker developing new engines with suppliers or, maybe, rivals. According to Automotive News John Lawler, Ford's vice chair overseeing strategy, partnerships and alliances, told the Bernstein Strategic Decisions Conference, "I don't think that consumers really think about powertrains the way they did 30 years ago". He told the conference, "Where [internal combustion engines] defined what a vehicle was — the horsepower, the displacement, the torque and everything about the vehicle — I think a lot of that is gone". Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. Part of this, Mr Lawler believes, is down to electrification, which allows automakers to increase power and torque, while reducing CO2 emissions, with hybrid or plug-in hybrid drivetrains. Mr Lawler posits this might lead automakers, including Ford, to develop next-generation engines with other companies. Doing so would save money that could help them compete with Chinese automakers. According to the vice chair, Ford needs "to be competitive against them not only on speed of development, software capability, electrical architecture capability, but also overall electrification capability". In 2022 Renault merged its Horse drivetrain division with that of Geely's Aurobay in the hopes of attracting customers for its engines and transmissions outside of the two automakers' stable of brands, which include Dacia, Volvo, Zeekr, and Lotus. It should be noted engine and drivetrain sharing between rival automakers, while not the norm, isn't completely unheard of. In the early 2000s Ford developed a V6 turbo-diesel in conjunction with the PSA Group, which was used in a wide variety of vehicles, including Australian Ford Territory, as well as the Citroen C5, Peugeot 407 and 607, and a whole host of Jaguar and Land Rover models. Other times, manufacturers just sign a supply agreement to fill a hole in their drivetrain lineup, such as when Toyota Europe used BMW diesel engines in the 2010s for a number of models, including the RAV4. Small manufacturers often rely exclusively on engines from other car makers, with Lotus, for example, using mills from Rover, Toyota and Mercedes-Benz. Ford is no stranger to collaborating with other car makers in other areas too. It currently shares a number of platforms with the Volkswagen Group, with the Volkswagen Amarok based on the Ford Ranger, and Volkswagen Transporter based on the Ford Transit Custom. Going the other way, the Ford Transit Connect is based on the Volkswagen Caddy, and the European Ford Explorer and Capri EVs are based Volkswagen MEB architecture. Prior to all this, Ford jointly developed a 10-speed automatic transmission for use in full-size pickup trucks with cross-town rival GM. MORE: Everything Ford Content originally sourced from: A senior Ford executive thinks customers no longer separate brands based on their petrol and diesel engines, and this might lead to the automaker developing new engines with suppliers or, maybe, rivals. According to Automotive News John Lawler, Ford's vice chair overseeing strategy, partnerships and alliances, told the Bernstein Strategic Decisions Conference, "I don't think that consumers really think about powertrains the way they did 30 years ago". He told the conference, "Where [internal combustion engines] defined what a vehicle was — the horsepower, the displacement, the torque and everything about the vehicle — I think a lot of that is gone". Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. Part of this, Mr Lawler believes, is down to electrification, which allows automakers to increase power and torque, while reducing CO2 emissions, with hybrid or plug-in hybrid drivetrains. Mr Lawler posits this might lead automakers, including Ford, to develop next-generation engines with other companies. Doing so would save money that could help them compete with Chinese automakers. According to the vice chair, Ford needs "to be competitive against them not only on speed of development, software capability, electrical architecture capability, but also overall electrification capability". In 2022 Renault merged its Horse drivetrain division with that of Geely's Aurobay in the hopes of attracting customers for its engines and transmissions outside of the two automakers' stable of brands, which include Dacia, Volvo, Zeekr, and Lotus. It should be noted engine and drivetrain sharing between rival automakers, while not the norm, isn't completely unheard of. In the early 2000s Ford developed a V6 turbo-diesel in conjunction with the PSA Group, which was used in a wide variety of vehicles, including Australian Ford Territory, as well as the Citroen C5, Peugeot 407 and 607, and a whole host of Jaguar and Land Rover models. Other times, manufacturers just sign a supply agreement to fill a hole in their drivetrain lineup, such as when Toyota Europe used BMW diesel engines in the 2010s for a number of models, including the RAV4. Small manufacturers often rely exclusively on engines from other car makers, with Lotus, for example, using mills from Rover, Toyota and Mercedes-Benz. Ford is no stranger to collaborating with other car makers in other areas too. It currently shares a number of platforms with the Volkswagen Group, with the Volkswagen Amarok based on the Ford Ranger, and Volkswagen Transporter based on the Ford Transit Custom. Going the other way, the Ford Transit Connect is based on the Volkswagen Caddy, and the European Ford Explorer and Capri EVs are based Volkswagen MEB architecture. Prior to all this, Ford jointly developed a 10-speed automatic transmission for use in full-size pickup trucks with cross-town rival GM. MORE: Everything Ford Content originally sourced from: A senior Ford executive thinks customers no longer separate brands based on their petrol and diesel engines, and this might lead to the automaker developing new engines with suppliers or, maybe, rivals. According to Automotive News John Lawler, Ford's vice chair overseeing strategy, partnerships and alliances, told the Bernstein Strategic Decisions Conference, "I don't think that consumers really think about powertrains the way they did 30 years ago". He told the conference, "Where [internal combustion engines] defined what a vehicle was — the horsepower, the displacement, the torque and everything about the vehicle — I think a lot of that is gone". Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. Part of this, Mr Lawler believes, is down to electrification, which allows automakers to increase power and torque, while reducing CO2 emissions, with hybrid or plug-in hybrid drivetrains. Mr Lawler posits this might lead automakers, including Ford, to develop next-generation engines with other companies. Doing so would save money that could help them compete with Chinese automakers. According to the vice chair, Ford needs "to be competitive against them not only on speed of development, software capability, electrical architecture capability, but also overall electrification capability". In 2022 Renault merged its Horse drivetrain division with that of Geely's Aurobay in the hopes of attracting customers for its engines and transmissions outside of the two automakers' stable of brands, which include Dacia, Volvo, Zeekr, and Lotus. It should be noted engine and drivetrain sharing between rival automakers, while not the norm, isn't completely unheard of. In the early 2000s Ford developed a V6 turbo-diesel in conjunction with the PSA Group, which was used in a wide variety of vehicles, including Australian Ford Territory, as well as the Citroen C5, Peugeot 407 and 607, and a whole host of Jaguar and Land Rover models. Other times, manufacturers just sign a supply agreement to fill a hole in their drivetrain lineup, such as when Toyota Europe used BMW diesel engines in the 2010s for a number of models, including the RAV4. Small manufacturers often rely exclusively on engines from other car makers, with Lotus, for example, using mills from Rover, Toyota and Mercedes-Benz. Ford is no stranger to collaborating with other car makers in other areas too. It currently shares a number of platforms with the Volkswagen Group, with the Volkswagen Amarok based on the Ford Ranger, and Volkswagen Transporter based on the Ford Transit Custom. Going the other way, the Ford Transit Connect is based on the Volkswagen Caddy, and the European Ford Explorer and Capri EVs are based Volkswagen MEB architecture. Prior to all this, Ford jointly developed a 10-speed automatic transmission for use in full-size pickup trucks with cross-town rival GM. MORE: Everything Ford Content originally sourced from:
7NEWS
7 hours ago
- 7NEWS
Ford might develop future engines with outside firms, says executive
A senior Ford executive thinks customers no longer separate brands based on their petrol and diesel engines, and this might lead to the automaker developing new engines with suppliers or, maybe, rivals. According to Automotive News John Lawler, Ford's vice chair overseeing strategy, partnerships and alliances, told the Bernstein Strategic Decisions Conference, 'I don't think that consumers really think about powertrains the way they did 30 years ago'. He told the conference, 'Where [internal combustion engines] defined what a vehicle was — the horsepower, the displacement, the torque and everything about the vehicle — I think a lot of that is gone'. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. Part of this, Mr Lawler believes, is down to electrification, which allows automakers to increase power and torque, while reducing CO2 emissions, with hybrid or plug-in hybrid drivetrains. Mr Lawler posits this might lead automakers, including Ford, to develop next-generation engines with other companies. Doing so would save money that could help them compete with Chinese automakers. According to the vice chair, Ford needs 'to be competitive against them not only on speed of development, software capability, electrical architecture capability, but also overall electrification capability'. In 2022 Renault merged its Horse drivetrain division with that of Geely's Aurobay in the hopes of attracting customers for its engines and transmissions outside of the two automakers' stable of brands, which include Dacia, Volvo, Zeekr, and Lotus. It should be noted engine and drivetrain sharing between rival automakers, while not the norm, isn't completely unheard of. In the early 2000s Ford developed a V6 turbo-diesel in conjunction with the PSA Group, which was used in a wide variety of vehicles, including Australian Ford Territory, as well as the Citroen C5, Peugeot 407 and 607, and a whole host of Jaguar and Land Rover models. Other times, manufacturers just sign a supply agreement to fill a hole in their drivetrain lineup, such as when Toyota Europe used BMW diesel engines in the 2010s for a number of models, including the RAV4. Small manufacturers often rely exclusively on engines from other car makers, with Lotus, for example, using mills from Rover, Toyota and Mercedes-Benz. Ford is no stranger to collaborating with other car makers in other areas too. It currently shares a number of platforms with the Volkswagen Group, with the Volkswagen Amarok based on the Ford Ranger, and Volkswagen Transporter based on the Ford Transit Custom.
